Who
Nevan C. Elam
CEO
Company insider
Files Form 4 as: CEO, Rezolute; Director, Savara; SVP & Head of Pulmonary Bus, Nektar Therapeutics.
In numbers
- Trades disclosed
- 69
- Buys
- 3
- Sells
- 2
- Bought
- $94K
- Sold
- $442K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 10 Mar 2006
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $40K8,004 at $4.99 | filing |
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $40K8,004 at $4.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $83K27,618 at $2.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $83K27,618 at $2.99 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $51K32,000 at $1.59 | filing |
| 9 Dec 2025filed 11 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Dec 2025filed 4 Dec 2025 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,860 at $0.00 | filing |
| 2 Dec 2025filed 4 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $8,5565,860 at $1.46 | filing |
| 2 Dec 2025filed 4 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $8,5581,473 at $5.81 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —317,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 27 Mar 2025filed 31 Mar 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $35K12,302 at $2.85 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Feb 2024filed 28 Feb 2024 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $8,4005,000 at $1.68 | filing |
| 23 Jan 2024filed 25 Jan 2024 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —340,000 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,758 at $0.00 | filing |
News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Nevan C. Elam; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.